Basal Cell Carcinoma

Perform focused lesion examination with dermoscopy and document greatest clinical diameter, anatomic site, border definition, prior treatment, and whether the lesion is primary or recurrent. Dermoscopy is useful for BCC diagnosis and may help predict histopathologic subtype, but biopsy is required when clinical and dermoscopic findings are equivocal. ScienceDirect+1ScienceDirectCurrent management of nonmelanoma skin cancersPubMedThe relation between dermoscopy and histopathology of basal ...

Choose a biopsy approach that will provide histologic confirmation and subtype information without compromising definitive management. The pathology report should be reviewed specifically for aggressive growth patterns—morpheaform, infiltrative, micronodular, or basosquamous differentiation—and for perineural invasion, because each shifts management toward complete margin assessment and closer surveillance. PubMed+2PubMedBasal Cell Carcinoma - StatPearls - NCBI BookshelfPubMedBasal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and PerspectivesScienceDirectBasal Cell Carcinoma Cell - an overview

Do not use routine TNM staging for ordinary localized BCC. Formal staging or additional extent assessment becomes relevant when there is advanced local disease, suspected nodal or distant disease, or concern for invasion of parotid gland, muscle, deep soft tissue, orbit, bone, or perineural structures. In these settings, obtain preoperative imaging directed to the threatened structure and plan treatment with dermatologic surgery, surgical oncology, radiation oncology, or a multidisciplinary tumor board. PubMed+1PubMedBasal Cell Carcinoma - StatPearls - NCBI BookshelfPubMedBasal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives

Offer complete surgery as first-line treatment for BCC. For high-risk or recurrent tumors and tumors at critical anatomic sites, micrographically controlled surgery should be offered because it provides real-time margin assessment while preserving uninvolved tissue. ScienceDirect+1ScienceDirectCurrent management of nonmelanoma skin cancersScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

Use conventional surgical excision with margin evaluation for appropriately selected localized tumors when anatomic location and histology do not require micrographic control. Surgery, including standard excision and Mohs micrographic surgery, is the principal curative approach for localized BCC; reported recurrence-free rates across properly selected local modalities range from 85% to 95%. ScienceDirect+1ScienceDirectGuidelines of care for the management of basal cell carcinomaCDCSkin Cancer Treatment (PDQ®) - NCI

Restrict curettage and electrodesiccation, cryotherapy, topical imiquimod, topical 5-fluorouracil, and other destructive approaches to low-risk superficial BCC when histologic margin control is not required. These modalities should not be used as routine therapy for recurrent, poorly defined, aggressive-subtype, or critical-site tumors because they do not provide the same complete margin assessment. ScienceDirect+2ScienceDirectDiagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines - ScienceDirectScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023CDCSkin Cancer Treatment (PDQ®) - NCI

Consider photodynamic therapy for superficial BCC and selected low-risk nodular BCC when surgery is not preferred or when a nonsurgical approach is appropriate. The tradeoff is that surgery remains standard first-line treatment, whereas photodynamic therapy is a selection-dependent alternative for low-risk disease. ScienceDirect+1ScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023CDCSkin Cancer Treatment (PDQ®) - NCI

Classify BCC as locally advanced when complete surgery or curative radiotherapy is not feasible without unacceptable morbidity, and as metastatic when nodal or distant spread is present. Before systemic therapy, define local extent with anatomy-directed imaging when deep soft tissue, muscle, parotid, orbit, bone, or perineural involvement is suspected. PubMed+1PubMedBasal Cell Carcinoma - StatPearls - NCBI BookshelfCDCSkin Cancer Treatment (PDQ®) - NCI

Offer a Hedgehog pathway inhibitor—vismodegib or sonidegib—for locally advanced or metastatic BCC. These agents are the recommended systemic first-line class for advanced disease; prolonged Smoothened inhibitor therapy can be followed by resistance. ScienceDirect+1ScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023PubMedEvaluation and Treatment of Skin Cancer in Patients With Immunosuppression - StatPearls - NCBI Bookshelf

Use cemiplimab for adults with locally advanced or metastatic BCC previously treated with a Hedgehog pathway inhibitor or for whom a Hedgehog pathway inhibitor is not appropriate. The FDA indication is supported by Study 1620, which enrolled advanced BCC after progression on a Hedgehog inhibitor, absence of objective response after 9 months of Hedgehog inhibitor therapy, or intolerance of prior Hedgehog inhibitor therapy. dailymed nlm nih+1dailymed nlm nihThese highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use Initial U.S. Approval: 2018dailymed nlm nihLIBTAYO

Assess immunotherapy candidacy carefully in patients with prior solid-organ transplantation, active autoimmune disease requiring systemic immunosuppression, or chronic viral infection because these populations were excluded from the pivotal advanced-BCC cemiplimab study. Discuss systemic treatment selection in a multidisciplinary setting when local therapy, radiation, and drug toxicities have competing functional consequences. dailymed nlm nih+2dailymed nlm nihThese highlights do not include all the information needed to use LIBTAYO safely and effectively. See full prescribing information for LIBTAYO. LIBTAYO® (cemiplimab-rwlc) injection, for intravenous use Initial U.S. Approval: 2018ScienceDirectCurrent management of nonmelanoma skin cancersScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

Perform long-term, often lifelong follow-up after BCC, with closer surveillance for patients with multiple, recurrent, or high-risk tumors. At each visit, examine the treated site for recurrence and perform a complete skin examination because subsequent skin cancers and precancerous lesions are common in this population. PubMedPubMedBasal Cell Carcinoma - StatPearls - NCBI Bookshelf

Maintain a low threshold to biopsy a new lesion within or adjacent to a prior treatment site, especially after topical, destructive, or radiation-based treatment where histologic margins were not assessed. Recurrent BCC, poorly defined borders, and aggressive histology should redirect management to complete margin-controlled treatment rather than repeated empiric destructive therapy. ScienceDirect+1ScienceDirectEuropean consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023PubMedBasal Cell Carcinoma - StatPearls - NCBI Bookshelf

For tumors with perineural invasion, monitor for new pain, paresthesia, weakness, or other focal neurologic symptoms and obtain imaging when symptoms or examination raise concern for clinical perineural spread. Perineural invasion can precede symptoms and is associated with a greater likelihood of extension beyond surgical margins. PubMedPubMedBasal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives